BON Announces Apple Polyphenol Commercial Order Signed
Bon Natural Life (BON) has secured a significant $12 million 24-month supply agreement with Shanghai Yunsheng to co-develop apple polyphenol-infused health solutions. The partnership focuses on combining BON's patented extraction technology for antioxidant-rich apple polyphenols with plant-based proteins.
The initiative targets multiple health benefits including weight management, metabolic health, lipid management, and reduction of age-related muscle atrophy. Market validation shows similar apple polyphenol blends generating $40 million in recurring revenue, with monthly sales exceeding 500,000 units.
BON aims to capitalize on this high-growth market through dual revenue streams: standalone nutraceuticals and functional food additives, while maintaining strong profit margins.
Bon Natural Life (BON) ha ottenuto un importante accordo di fornitura di 12 milioni di dollari della durata di 24 mesi con Shanghai Yunsheng per co-sviluppare soluzioni salutari infuse con polifenoli di mela. La partnership si concentra sulla combinazione della tecnologia di estrazione brevettata di BON per polifenoli di mela ricchi di antiossidanti con proteine vegetali.
L'iniziativa mira a diversi benefici per la salute, tra cui la gestione del peso, la salute metabolica, la gestione dei lipidi e la riduzione dell'atrofia muscolare legata all'età. La validazione del mercato mostra che miscele simili di polifenoli di mela generano 40 milioni di dollari di entrate ricorrenti, con vendite mensili che superano le 500.000 unità.
BON punta a capitalizzare su questo mercato in rapida crescita attraverso due flussi di entrate: nutraceutici autonomi e additivi alimentari funzionali, mantenendo forti margini di profitto.
Bon Natural Life (BON) ha asegurado un importante acuerdo de suministro de 12 millones de dólares por 24 meses con Shanghai Yunsheng para co-desarrollar soluciones de salud infusionadas con polifenoles de manzana. La asociación se centra en combinar la tecnología de extracción patentada de BON para polifenoles de manzana ricos en antioxidantes con proteínas vegetales.
La iniciativa tiene como objetivo múltiples beneficios para la salud, incluyendo el manejo del peso, la salud metabólica, la gestión de lípidos y la reducción de la atrofia muscular relacionada con la edad. La validación del mercado muestra que mezclas similares de polifenoles de manzana generan 40 millones de dólares en ingresos recurrentes, con ventas mensuales que superan las 500,000 unidades.
BON busca capitalizar este mercado de alto crecimiento a través de dos flujos de ingresos: nutracéuticos independientes y aditivos alimentarios funcionales, manteniendo márgenes de beneficio sólidos.
Bon Natural Life (BON)는 상하이 윈셍과 함께 사과 폴리페놀 건강 솔루션을 공동 개발하기 위해 1,200만 달러의 24개월 공급 계약을 체결했습니다. 이 파트너십은 BON의 항산화 성분이 풍부한 사과 폴리페놀에 대한 특허 추출 기술과 식물성 단백질을 결합하는 데 중점을 두고 있습니다.
이 이니셔티브는 체중 관리, 대사 건강, 지질 관리 및 노화 관련 근육 위축 감소를 포함한 여러 건강 이점을 목표로 합니다. 시장 검증에 따르면 유사한 사과 폴리페놀 혼합물이 4천만 달러의 반복 수익을 생성하며, 월 판매량이 500,000개를 초과합니다.
BON은 독립적인 건강 보조 식품과 기능성 식품 첨가제를 통해 이 고성장 시장을 활용하고 강력한 이익률을 유지하는 것을 목표로 하고 있습니다.
Bon Natural Life (BON) a sécurisé un important accord de fourniture de 12 millions de dollars sur 24 mois avec Shanghai Yunsheng pour co-développer des solutions de santé infusées de polyphénols de pomme. Le partenariat se concentre sur la combinaison de la technologie d'extraction brevetée de BON pour les polyphénols de pomme riches en antioxydants avec des protéines végétales.
L'initiative vise plusieurs bénéfices pour la santé, y compris la gestion du poids, la santé métabolique, la gestion des lipides et la réduction de l'atrophie musculaire liée à l'âge. La validation du marché montre que des mélanges similaires de polyphénols de pomme génèrent 40 millions de dollars de revenus récurrents, avec des ventes mensuelles dépassant les 500 000 unités.
BON vise à capitaliser sur ce marché à forte croissance grâce à deux sources de revenus : des nutraceutiques autonomes et des additifs alimentaires fonctionnels, tout en maintenant des marges bénéficiaires solides.
Bon Natural Life (BON) hat einen bedeutenden 12 Millionen Dollar Liefervertrag über 24 Monate mit Shanghai Yunsheng abgeschlossen, um gemeinsam Gesundheitslösungen mit Apfelpolyphenolen zu entwickeln. Die Partnerschaft konzentriert sich auf die Kombination von BONs patentierter Extraktionstechnologie für antioxidansreiche Apfelpolyphenole mit pflanzlichen Proteinen.
Die Initiative zielt auf mehrere Gesundheitsvorteile ab, darunter Gewichtsmanagement, metabolische Gesundheit, Lipidmanagement und die Reduzierung altersbedingter Muskelatrophie. Marktvalidierung zeigt, dass ähnliche Apfelpolyphenol-Mischungen 40 Millionen Dollar wiederkehrende Einnahmen generieren, wobei die monatlichen Verkäufe 500.000 Einheiten übersteigen.
BON plant, von diesem wachstumsstarken Markt durch zwei Einnahmequellen zu profitieren: eigenständige Nutraceuticals und funktionale Lebensmittelzusätze, während es starke Gewinnmargen aufrechterhält.
- Secured $12M supply agreement with major distributor Shanghai Yunsheng
- Market validation shows strong demand with similar products generating $40M recurring revenue
- Dual revenue streams from standalone nutraceuticals and food additives
- Proprietary patented extraction technology
- Strong market position as premier apple polyphenol supplier
- None.
Insights
BON's $12M supply agreement with Shanghai Yunsheng represents a significant commercial milestone for a company with a market cap of just
The 24-month structure provides revenue visibility of approximately
What's particularly compelling is the market validation referenced - comparable products generating
The dual monetization approach (standalone nutraceuticals and functional food additives) creates multiple revenue streams from the same core technology, potentially maximizing return on R&D investment. Management's emphasis on "disciplined margin control" suggests focus on profitability, not just top-line growth.
While BON appears positioned for growth in the functional ingredients space, investors should monitor execution of this agreement and corresponding revenue recognition in upcoming quarters.
BON's apple polyphenol agreement represents a strategic positioning in one of nutrition's fastest-growing categories: functional protein formulations with clinically-validated bioactives. The
The company is intelligently targeting the convergence of two robust trends: protein supplements (a mature category with established consumer adoption) and polyphenols (bioactive compounds with strong scientific validation). By combining their patented apple polyphenol extraction technology with protein formulations, they're creating differentiated products addressing specific health outcomes.
The mentioned clinical validation for lipid management, body composition, and muscle preservation represents the evolution of supplements toward condition-specific efficacy. This positions BON's ingredients upstream in formulations that command price premiums in the marketplace.
What makes this particularly notable is the referenced market validation—comparable formulations achieving
Their vertical integration should enable both quality control and margin protection in a competitive ingredient landscape.
XI'AN, China, April 11, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced a groundbreaking 24-month supply agreement worth
Protein supplements have evolved into a mainstream wellness staple over decades, cementing their role in fitness regimens, immune health protocols, and longevity-focused nutrition. The strategic incorporation of apple polyphenols into these formulations now unlocks targeted benefits-clinically validated lipid management, enhanced body composition outcomes, and mitigation of age-related muscle atrophy-positioning this innovation at the convergence of proven demand and novel functionality.
Early market validation proves compelling-comparable apple polyphenol blends have achieved blockbuster status since launch, selling over half a million units monthly and generating
“As one of the world's premier apple polyphenol suppliers, we're leveraging our vertically integrated supply chain to dominate this high-growth niche,” said Yongwei Hu, Chairman and CEO of the Company, “the company anticipates compounding revenue streams from the ingredient's dual applications-both as a standalone nutraceutical and as a functional food additive-while maintaining disciplined margin control to maximize shareholder returns.”
About Bon Natural Life Limited ("BON")
BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit the Company's website at http://www.bnlus.com.
For more information, please contact:
Cindy Liu | IR
Email: bonnatural@appchem.cn
Safe Harbor Statement
This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
FAQ
What is the value and duration of BON's new supply agreement with Shanghai Yunsheng?
How much revenue do similar apple polyphenol products generate in the market?
What health benefits does BON's apple polyphenol-protein formulation target?
How does BON plan to monetize its apple polyphenol products?
